Association Between Severe Kidney Impairment at Treatment Initiation and Mortality in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) predominantly affects the aging demographic, in whom excessive immunosuppression correlates with poor prognosis. While treatment strategies have shifted toward minimizing immunosuppression, achieving disease control in an aging population remains challenging, and improvements in treatment outcomes have plateaued (1). Despite these recent advances, overall improvement in patient outcomes remains limited. We previously reported that patients exhibiting severe kidney impairment two weeks post-treatment initiation had poor six months prognosis (2).